What is the recommended cryoprecipitate dosing for adults and children, including weight‑based calculations and adjustments for low fibrinogen or massive hemorrhage?

Cryoprecipitate Dosing Recommendations

For adults with significant bleeding and hypofibrinogenemia, administer 50 mg/kg of cryoprecipitate (approximately 15-20 units or 2 pools in a 70 kg adult) to achieve a target fibrinogen level of 1.5-2.0 g/L, with pediatric dosing at 5-10 ml/kg. 1

Adult Dosing

Standard Initial Dose

• 50 mg/kg of cryoprecipitate is the recommended initial dose for hypofibrinogenemia with bleeding 1
• This translates to approximately 15-20 units in a 70 kg adult (equivalent to 2 pools of cryoprecipitate) 1
• Each pool typically contains 5 units with approximately 2 g of fibrinogen 2

Weight-Based Calculation

• Two units of cryoprecipitate per 10 kg body weight raises plasma fibrinogen concentration by approximately 1 g/L 3
• A single unit contains 400-450 mg of fibrinogen 2
• The fibrinogen concentration in cryoprecipitate varies between 15-17 g/L 3

Target Fibrinogen Levels

• Maintain fibrinogen >1.5-2.0 g/L during major hemorrhage 1
• Maintain fibrinogen >2.0 g/L specifically in obstetric hemorrhage 2
• Cryoprecipitate is indicated when fibrinogen is <80-100 mg/dL with excessive microvascular bleeding 4, 5
• Transfusion is rarely indicated if fibrinogen >150 mg/dL in non-pregnant patients 5

Pediatric Dosing

Volume-Based Approach

• 5-10 ml/kg is the recommended dose for children 2, 6
• Blood components should be prescribed by volume rather than units in pediatric patients 2, 6
• Neonates require components specified for neonatal use, including cytomegalovirus-negative products 2

Massive Hemorrhage Protocols

Trauma-Specific Ratios

• 1 unit of cryoprecipitate per 7-8 units of RBCs provides optimal survival benefit in massive transfusion 7
• RBC:Cryo ratios ≤8:1 were associated with significant survival benefit, while ratios >8:1 showed no mortality reduction 7
• When using whole blood, cryoprecipitate should be considered after 10 units versus 7 units with component therapy 8

Timing Considerations

• Administer cryoprecipitate within 90 minutes of hospital arrival when possible 9
• In practice, median time to cryoprecipitate issue for patients with fibrinogen <1 g/L is 2.5 hours (IQR 1.2-4.3 hours) 10
• Early administration (within 60 minutes) is feasible and maintains fibrinogen >1.8 g/L during active hemorrhage 9

Dosing Adjustments and Monitoring

Expected Fibrinogen Response

• Each unit of cryoprecipitate increases fibrinogen by approximately 0.06 g/L 11
• A dose of 8.7 units causes a mean increase of 0.55 g/L in patients not receiving concurrent plasma 11
• Repeat doses should be guided by thrombelastometric monitoring and laboratory fibrinogen levels 1

Clinical Context Modifications

• Cardiac surgery: Initial dose 3-4 g fibrinogen equivalent (approximately 2 pools) 1
• Obstetric hemorrhage: Maintain higher threshold (>2.0 g/L) with aggressive early replacement 2
• Liver disease with bleeding: Maintain fibrinogen >1.0 g/L 2

Important Caveats

Product Composition

• Cryoprecipitate contains not only fibrinogen but also von Willebrand factor, factor VIII, factor XIII, and fibronectin 3
• This multi-component nature may provide functional hemostatic advantages beyond isolated fibrinogen replacement 3

Administration Considerations

• Use standard blood giving set with 170-200 μm filter 2
• Once thawed, cryoprecipitate can be kept at ambient temperature for 4 hours but should not be refrigerated again 2
• ABO-compatible pooling is required before transfusion in adults 3

Monitoring Limitations

• Laboratory Clauss fibrinogen assays may overestimate actual fibrinogen concentration in the presence of hydroxyethyl starch 1
• Point-of-care viscoelastic testing (thrombelastometry) is preferred during active hemorrhage when laboratory turnaround is too slow 2